^
    Back
    Association details:
    Biomarker:EGFR mutation
    Cancer:Lung Adenocarcinoma
    Drug:Focus V (anlotinib) (Multi-tyrosine kinase inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

    Excerpt:
    ...- EGFRALKROS1 wildtype or unknown,or patients with EGFRALKROS1 mutations but refuse to receive corresponding inhibitors' treatment...
    Trial ID:
    NCT03636685
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Observational clinical study of anlotinib hydrochloride combined with gefitinib in first-line treatment of EGFR-sensitive mutations in advanced NSCLC

    Excerpt:
    ......
    Trial ID:
    ChiCTR2100044011
    Less C2 evidence
    Evidence Level:
    Resistant: C4 – Case Studies
    Source:
    Zhongguo Fei Ai Za Zhi
    Title:

    Response of Lung Adenocarcinoma Harbouring Sensitizing EGFR Mutation to the Fourth-line Combination Treatment of Pembrolizumab and Anlotinib

    Published date:
    10/11/2021
    Excerpt:
    Herein we reported a case that till January 12, 2021, an 82-year-old female with EGFR-mutant advanced lung adenocarcinoma received a surprising progression-free survival (PFS) benefit of over 21 months from the combination therapy of pembrolizumab and anlotinib after her failure of treatments of osimertinib, chemotherapy and anlotinib-monotherapy.
    DOI:
    10.3779/j.issn.1009-3419.2021.102.25